JP4719144B2 - ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 - Google Patents

ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 Download PDF

Info

Publication number
JP4719144B2
JP4719144B2 JP2006505892A JP2006505892A JP4719144B2 JP 4719144 B2 JP4719144 B2 JP 4719144B2 JP 2006505892 A JP2006505892 A JP 2006505892A JP 2006505892 A JP2006505892 A JP 2006505892A JP 4719144 B2 JP4719144 B2 JP 4719144B2
Authority
JP
Japan
Prior art keywords
group
compound
mmol
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006505892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521335A5 (cg-RX-API-DMAC10.html
JP2006521335A (ja
Inventor
マシュー リーズ,
アラン ピュロヒット,
マイケル ジョン リード,
サイモン ポール ニューマン,
スリンダー クマール チャンダー,
ファブリス ジョーダン,
バリー ビクター ロイド ポッター,
Original Assignee
ステリックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0306717A external-priority patent/GB0306717D0/en
Priority claimed from GB0315885A external-priority patent/GB0315885D0/en
Application filed by ステリックス リミテッド filed Critical ステリックス リミテッド
Publication of JP2006521335A publication Critical patent/JP2006521335A/ja
Publication of JP2006521335A5 publication Critical patent/JP2006521335A5/ja
Application granted granted Critical
Publication of JP4719144B2 publication Critical patent/JP4719144B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2006505892A 2003-03-24 2004-02-20 ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 Expired - Fee Related JP4719144B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0306717.0 2003-03-24
GB0306717A GB0306717D0 (en) 2003-03-24 2003-03-24 Compound
GB0315885.4 2003-07-07
GB0315885A GB0315885D0 (en) 2003-07-07 2003-07-07 Compound
PCT/GB2004/000705 WO2004085459A1 (en) 2003-03-24 2004-02-20 Oestrogen derivatives as inhibitors of steroid sulphatase

Publications (3)

Publication Number Publication Date
JP2006521335A JP2006521335A (ja) 2006-09-21
JP2006521335A5 JP2006521335A5 (cg-RX-API-DMAC10.html) 2007-03-01
JP4719144B2 true JP4719144B2 (ja) 2011-07-06

Family

ID=33099976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505892A Expired - Fee Related JP4719144B2 (ja) 2003-03-24 2004-02-20 ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体

Country Status (14)

Country Link
US (1) US7893284B2 (cg-RX-API-DMAC10.html)
EP (1) EP1608671B1 (cg-RX-API-DMAC10.html)
JP (1) JP4719144B2 (cg-RX-API-DMAC10.html)
AT (1) ATE454395T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004224053B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0408703A (cg-RX-API-DMAC10.html)
CA (1) CA2520142C (cg-RX-API-DMAC10.html)
DE (1) DE602004024966D1 (cg-RX-API-DMAC10.html)
DK (1) DK1608671T3 (cg-RX-API-DMAC10.html)
EA (1) EA011123B1 (cg-RX-API-DMAC10.html)
ES (1) ES2339450T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA05010339A (cg-RX-API-DMAC10.html)
PL (1) PL378577A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004085459A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
WO2008090517A2 (en) * 2007-01-26 2008-07-31 Piramal Life Sciences Limited Enriched plant extract, compound, and methods for the treatment of proliferative disorders
EP2149371A1 (en) 2008-07-28 2010-02-03 PregLem S.A. Use of steroid sulfatase inhibitors for the treatment of preterm labor
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
JP2012524778A (ja) * 2009-04-22 2012-10-18 プレジデント アンド フェロウズ オブ ハーバード カレッジ 血管新生阻害剤
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
DK2935307T3 (en) 2012-12-18 2018-07-30 Univ Washington NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
AU2017283878A1 (en) * 2016-06-15 2019-01-03 Sony Corporation Information processing device, observation system, observation method, and program
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US6288050B1 (en) * 1997-07-18 2001-09-11 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331987B (en) * 1997-12-04 2002-11-27 Imperial College Polycyclic sulphamate inhibitors of oestrone sulphatase
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
JP2002517449A (ja) * 1998-06-10 2002-06-18 ステリックス リミテッド エストロンスルファターゼの阻害のための腫瘍壊死因子aおよび2−メトキシエストロン−3−o−スルファメートを有する薬学的組成物
JP5042411B2 (ja) * 1999-04-30 2012-10-03 ステリックス リミテッド 抗腫瘍剤としてのエストロン誘導体の使用
JPWO2001081364A1 (ja) * 2000-04-24 2004-01-08 協和醗酵工業株式会社 エストラ−1,3,5(10)−トリエン誘導体
CA2408751A1 (en) * 2000-05-11 2001-11-15 Robert Henry Hesse 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity
CA2418479C (en) * 2000-08-18 2007-12-18 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
WO2002062347A1 (en) 2001-02-05 2002-08-15 Oncology Sciences Corporation Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis
GB0421106D0 (en) * 2004-09-22 2004-10-27 Sterix Ltd Compound

Also Published As

Publication number Publication date
WO2004085459A1 (en) 2004-10-07
ATE454395T1 (de) 2010-01-15
EA011123B1 (ru) 2008-12-30
BRPI0408703A (pt) 2006-03-07
US7893284B2 (en) 2011-02-22
DE602004024966D1 (de) 2010-02-25
HK1082258A1 (en) 2006-06-02
AU2004224053B2 (en) 2011-06-09
EP1608671A1 (en) 2005-12-28
AU2004224053A1 (en) 2004-10-07
DK1608671T3 (da) 2010-05-10
PL378577A1 (pl) 2006-05-02
MXPA05010339A (es) 2005-12-14
US20060094696A1 (en) 2006-05-04
EA200501426A1 (ru) 2006-06-30
CA2520142A1 (en) 2004-10-07
ES2339450T3 (es) 2010-05-20
CA2520142C (en) 2011-01-04
EP1608671B1 (en) 2010-01-06
JP2006521335A (ja) 2006-09-21

Similar Documents

Publication Publication Date Title
JP2006521335A (ja) ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体
US6054446A (en) Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
JP5582604B2 (ja) アロマターゼインヒビターとしてのスルファメート基を含む1,2,4−トリアゾール誘導体
US8003783B2 (en) 17B-hydroxysteroid dehydrogenase inhibitors
JP4958377B2 (ja) ステロイドスルファターゼのインヒビターとしてのエストロゲン−17−スルファメート
JP5042411B2 (ja) 抗腫瘍剤としてのエストロン誘導体の使用
JP4771660B2 (ja) アロマターゼインヒビターとしてのスルファメート基を含む1,2,4−トリアゾール誘導体
JP4931312B2 (ja) ステロイドスルファターゼのインヒビターとしてのハロゲン化スルファメート−、ホスホネート−、チオホスホネート−、スルホネート−、およびスルホンアミド−化合物
JP2003519658A (ja) ステロイド構造を含む薬学的組成物およびそれらの使用
JP4553586B2 (ja) ステロイドスルファターゼを阻害するための、ステロイド化合物
CA2576614A1 (en) 2-substituted estrogen sulphamates for inhibition of steroid sulphatase
HK1082258B (en) Oestrogen derivatives as inhibitors of steroid sulphatase
CN100384868C (zh) 类固醇硫酸酯酶抑制剂的雌激素衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110217

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110401

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees